Tracer Shows Which Lung Cancer Patients May Benefit from Tyrosine Kinase Inhibitors (1 of 1) (IMAGE)

American Association for the Advancement of Science (AAAS)

Tracer Shows Which Lung Cancer Patients May Benefit from Tyrosine Kinase Inhibitors (1 of 1)

Caption

Representative CT and PET/CT images of 3 patients with non-small cell lung cancers. (A) Patient with an EGFR exon 19 E746-A750 deletion who did not receive EGFR-TKI treatment, with a tumor in the right upper lobe of the lung (red arrow) (B) Patient with an EGFR exon 21 L858R point mutation, 15 days after gefitinib treatment. Tumor in the right upper lung lobe (red arrow) and spinal metastasis (yellow arrow) were observed both on 18F-MPG and 18F-FDG images. (C) Patient with wild-type EGFR who did not receive EGFR-TKI treatment. Tumor in the left hilum (red arrow) was prominently observed on the 18F-MPG image.

Credit

X. Sun <i>et al., Science Translational Medicine </i>(2018)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.